BridgeBio Pharma Inc 2024年度报告

(Mark One) Securities registered pursuant to section 12(g) of the Act:NONE Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesցNoտ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesտNoց Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements forthe past 90 days. YesցNoտ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesցNoտ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filerցAccelerated filerտNon-accelerated filerտSmaller reporting companyտEmerging growth companyտ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.տ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 726(b)) by the registered public accounting firm that prepared or issued its auditreport.ց Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).տ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesտNoց The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of theregistrant’s Common Stock on The Nasdaq Global Select Market on June 30, 2024 was approximately $3,729.4 million. Shares of the registrant’s Common Stock heldby each executive officer and director and by each other person who may be deemed an affiliate of the Registrant have been excluded from this computation. Thedetermination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes. On February 13, 2025, there were 190,188,626 shares of the registrant’s Common Stock issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s definitive Proxy Statement to be issued in conjunction with the registrant’s 2025 Annual Meeting of Stockholders,which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this AnnualReport. Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K. BRIDGEBIO PHARMA, INC.2024 Form 10-K Annual Report Table of Contents PART IBusiness .............................................................................................................................................. Item 1.1Item 1A.Risk Factors ........................................................................................................................................50Item 1B.Unresolved Staff Comments ...............................................................................................................118Item 1C.Cybersecurity ......................................................................................................................................118Item 2.Properties ............................................................................................................................................119Item 3.Legal Proceedings ...............................................................................................................................119Item 4.Mine Safety Disclosures .....................................................................................................................119PART IIItem 5.Market for the Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities ............................................................